Post-marketing drug safety measures for the attainment of safer and more effective use of drug

Tatsuo Kurokawa

Research output: Contribution to journalArticle

Abstract

In contrast with the 20th century's dramatic improvements in the direct and/or hazardous toxicity of drugs, indirect toxicity and/or long-term safety concerns such as relation of cancer risk and TNF-alpha receptor blockers have caused significant complexity in post-marketing surveillance (PMS) scenery. The post-marketing phase of drugs and their safety measures now appear to be much more complicated and heavier than decades ago. The spontaneous adverse drug reaction (ADR) reporting system which has been one of the main pillars of PMS measures for almost 50 years may have to be reviewed in terms of its effectiveness, and may need augmentation from medical data bases. Only a pharmacoepidemiological analysis and integration of the output with a conventional spontaneous reporting approach offers a chance to satisfy the current complex safety issues. Today's tendency toward practical saturation at medical/pharmaceutical frontiers, by regulatory authorities and safety divisions of pharmaceutical companies with ever-increasing can also be pointed out. Such phenomena may actually reduce the productivity of safety measures and also jeopardize the maintenance of an acceptable risk/benefit drug ratio. To alleviate these potential negative implications, establishment of a consortium to act as a sentinel that would gather up-to-date and essential safety information, including epidemiological data, from all sources and provide it plus recommendations to all stakeholders can be suggested. Through such activities, we could expect significant improvement of drug safety measures in post-marketing phase which would eFFectively cover not only new drugs but also generic and bio-simulated drugs.

Original languageEnglish
Pages (from-to)885-890
Number of pages6
JournalYakugaku Zasshi
Volume131
Issue number6
DOIs
Publication statusPublished - 2011
Externally publishedYes

Fingerprint

Marketing
Safety
Pharmaceutical Preparations
Adverse Drug Reaction Reporting Systems
Generic Drugs
Tumor Necrosis Factor Receptors
Information Storage and Retrieval
Drug-Related Side Effects and Adverse Reactions
Tumor Necrosis Factor-alpha
Maintenance
Databases
Neoplasms

Keywords

  • Adverse drug reaction
  • Drug data base
  • Drug monitoring system
  • Drug safety
  • Epidemiological study
  • Yakugai

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Post-marketing drug safety measures for the attainment of safer and more effective use of drug. / Kurokawa, Tatsuo.

In: Yakugaku Zasshi, Vol. 131, No. 6, 2011, p. 885-890.

Research output: Contribution to journalArticle

@article{f3799b393b0f479db1967a6a379dcc1d,
title = "Post-marketing drug safety measures for the attainment of safer and more effective use of drug",
abstract = "In contrast with the 20th century's dramatic improvements in the direct and/or hazardous toxicity of drugs, indirect toxicity and/or long-term safety concerns such as relation of cancer risk and TNF-alpha receptor blockers have caused significant complexity in post-marketing surveillance (PMS) scenery. The post-marketing phase of drugs and their safety measures now appear to be much more complicated and heavier than decades ago. The spontaneous adverse drug reaction (ADR) reporting system which has been one of the main pillars of PMS measures for almost 50 years may have to be reviewed in terms of its effectiveness, and may need augmentation from medical data bases. Only a pharmacoepidemiological analysis and integration of the output with a conventional spontaneous reporting approach offers a chance to satisfy the current complex safety issues. Today's tendency toward practical saturation at medical/pharmaceutical frontiers, by regulatory authorities and safety divisions of pharmaceutical companies with ever-increasing can also be pointed out. Such phenomena may actually reduce the productivity of safety measures and also jeopardize the maintenance of an acceptable risk/benefit drug ratio. To alleviate these potential negative implications, establishment of a consortium to act as a sentinel that would gather up-to-date and essential safety information, including epidemiological data, from all sources and provide it plus recommendations to all stakeholders can be suggested. Through such activities, we could expect significant improvement of drug safety measures in post-marketing phase which would eFFectively cover not only new drugs but also generic and bio-simulated drugs.",
keywords = "Adverse drug reaction, Drug data base, Drug monitoring system, Drug safety, Epidemiological study, Yakugai",
author = "Tatsuo Kurokawa",
year = "2011",
doi = "10.1248/yakushi.131.885",
language = "English",
volume = "131",
pages = "885--890",
journal = "Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "6",

}

TY - JOUR

T1 - Post-marketing drug safety measures for the attainment of safer and more effective use of drug

AU - Kurokawa, Tatsuo

PY - 2011

Y1 - 2011

N2 - In contrast with the 20th century's dramatic improvements in the direct and/or hazardous toxicity of drugs, indirect toxicity and/or long-term safety concerns such as relation of cancer risk and TNF-alpha receptor blockers have caused significant complexity in post-marketing surveillance (PMS) scenery. The post-marketing phase of drugs and their safety measures now appear to be much more complicated and heavier than decades ago. The spontaneous adverse drug reaction (ADR) reporting system which has been one of the main pillars of PMS measures for almost 50 years may have to be reviewed in terms of its effectiveness, and may need augmentation from medical data bases. Only a pharmacoepidemiological analysis and integration of the output with a conventional spontaneous reporting approach offers a chance to satisfy the current complex safety issues. Today's tendency toward practical saturation at medical/pharmaceutical frontiers, by regulatory authorities and safety divisions of pharmaceutical companies with ever-increasing can also be pointed out. Such phenomena may actually reduce the productivity of safety measures and also jeopardize the maintenance of an acceptable risk/benefit drug ratio. To alleviate these potential negative implications, establishment of a consortium to act as a sentinel that would gather up-to-date and essential safety information, including epidemiological data, from all sources and provide it plus recommendations to all stakeholders can be suggested. Through such activities, we could expect significant improvement of drug safety measures in post-marketing phase which would eFFectively cover not only new drugs but also generic and bio-simulated drugs.

AB - In contrast with the 20th century's dramatic improvements in the direct and/or hazardous toxicity of drugs, indirect toxicity and/or long-term safety concerns such as relation of cancer risk and TNF-alpha receptor blockers have caused significant complexity in post-marketing surveillance (PMS) scenery. The post-marketing phase of drugs and their safety measures now appear to be much more complicated and heavier than decades ago. The spontaneous adverse drug reaction (ADR) reporting system which has been one of the main pillars of PMS measures for almost 50 years may have to be reviewed in terms of its effectiveness, and may need augmentation from medical data bases. Only a pharmacoepidemiological analysis and integration of the output with a conventional spontaneous reporting approach offers a chance to satisfy the current complex safety issues. Today's tendency toward practical saturation at medical/pharmaceutical frontiers, by regulatory authorities and safety divisions of pharmaceutical companies with ever-increasing can also be pointed out. Such phenomena may actually reduce the productivity of safety measures and also jeopardize the maintenance of an acceptable risk/benefit drug ratio. To alleviate these potential negative implications, establishment of a consortium to act as a sentinel that would gather up-to-date and essential safety information, including epidemiological data, from all sources and provide it plus recommendations to all stakeholders can be suggested. Through such activities, we could expect significant improvement of drug safety measures in post-marketing phase which would eFFectively cover not only new drugs but also generic and bio-simulated drugs.

KW - Adverse drug reaction

KW - Drug data base

KW - Drug monitoring system

KW - Drug safety

KW - Epidemiological study

KW - Yakugai

UR - http://www.scopus.com/inward/record.url?scp=79958068507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958068507&partnerID=8YFLogxK

U2 - 10.1248/yakushi.131.885

DO - 10.1248/yakushi.131.885

M3 - Article

C2 - 21628973

AN - SCOPUS:79958068507

VL - 131

SP - 885

EP - 890

JO - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

JF - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

SN - 0031-6903

IS - 6

ER -